Bradley Pharmaceuticals comprised Doak Dermatologics, specialized in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.

Doak Dermatologics was the division of Bradley Pharmaceuticals, that marketed products to dermatologists.

Adoxa (doxycycline) was an antibiotic intended to treat mild to severe acne.

Among the most prescribed ones were Entsol which is a respiratory therapeutic product and Pamine which is intended to treat digestive problems.

The merger was completed on February 21, 2008, and Bradley became an integral part of Nycomed.